GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pfenex Inc (AMEX:PFNX) » Definitions » Asset Turnover

Pfenex (Pfenex) Asset Turnover : 0.01 (As of Jun. 2020)


View and export this data going back to 2014. Start your Free Trial

What is Pfenex Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Pfenex's Revenue for the three months ended in Jun. 2020 was $0.78 Mil. Pfenex's Total Assets for the quarter that ended in Jun. 2020 was $89.28 Mil. Therefore, Pfenex's Asset Turnover for the quarter that ended in Jun. 2020 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. Pfenex's annualized ROE % for the quarter that ended in Jun. 2020 was -52.62%. It is also linked to ROA % through Du Pont Formula. Pfenex's annualized ROA % for the quarter that ended in Jun. 2020 was -46.29%.


Pfenex Asset Turnover Historical Data

The historical data trend for Pfenex's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfenex Asset Turnover Chart

Pfenex Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Asset Turnover
Get a 7-Day Free Trial 0.10 0.51 0.32 0.19 0.61

Pfenex Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.23 0.28 0.01 0.01

Competitive Comparison of Pfenex's Asset Turnover

For the Biotechnology subindustry, Pfenex's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfenex's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pfenex's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Pfenex's Asset Turnover falls into.



Pfenex Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Pfenex's Asset Turnover for the fiscal year that ended in Dec. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2019 )/( (Total Assets (A: Dec. 2018 )+Total Assets (A: Dec. 2019 ))/ count )
=50.326/( (81.278+84.887)/ 2 )
=50.326/83.0825
=0.61

Pfenex's Asset Turnover for the quarter that ended in Jun. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2020 )/( (Total Assets (Q: Mar. 2020 )+Total Assets (Q: Jun. 2020 ))/ count )
=0.781/( (92.777+85.773)/ 2 )
=0.781/89.275
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Pfenex  (AMEX:PFNX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Pfenex's annulized ROE % for the quarter that ended in Jun. 2020 is

ROE %**(Q: Jun. 2020 )
=Net Income/Total Stockholders Equity
=-41.324/78.534
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-41.324 / 3.124)*(3.124 / 89.275)*(89.275/ 78.534)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1322.79 %*0.035*1.1368
=ROA %*Equity Multiplier
=-46.29 %*1.1368
=-52.62 %

Note: The Net Income data used here is four times the quarterly (Jun. 2020) net income data. The Revenue data used here is four times the quarterly (Jun. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Pfenex's annulized ROA % for the quarter that ended in Jun. 2020 is

ROA %(Q: Jun. 2020 )
=Net Income/Total Assets
=-41.324/89.275
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-41.324 / 3.124)*(3.124 / 89.275)
=Net Margin %*Asset Turnover
=-1322.79 %*0.035
=-46.29 %

Note: The Net Income data used here is four times the quarterly (Jun. 2020) net income data. The Revenue data used here is four times the quarterly (Jun. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Pfenex Asset Turnover Related Terms

Thank you for viewing the detailed overview of Pfenex's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfenex (Pfenex) Business Description

Traded in Other Exchanges
N/A
Address
10790 Roselle Street, San Diego, CA, USA, 92121
Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.
Executives
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Phillip M Schneider director GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Jason Grenfell-gardner director 105 LINCOLN AVENUE BUENA NJ 08310
Patrick K. Lucy officer: Chief Business Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Robin Campbell director C/O PFENEX INC., 10790 ROSELLE STREET SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Mack Taylor director C/O PFENEX, INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Evert B. Schimmelpennink director, officer: See Remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Shawn Scranton officer: Chief Operating Officer C/O PFENEX INC 10790 ROSELLE STREET SAN DIEGO CA 92121
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Lorianne Masuoka director C/O PFENEX INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Newtyn Management, Llc 10 percent owner 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Weiss Asset Management Lp 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Wam Gp Llc 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116